NCT05929235 - A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

January 30, 2027

Conditions

Advanced Solid Tumors CancerAdvanced Urothelial CarcinomaOral Drug AdministrationOpen Label

Interventions

DRUG

FX-909

FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.

Trial Locations (12)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

10065

RECRUITING

Memorial Slone Kettering Cancer Center, New York

27514

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

44195

RECRUITING

The Cleveland Clinic Foundation, Cleveland

78229

COMPLETED

New Experimental Therapeutics of San Antonio (NEXT), San Antonio

COMPLETED

South Texas Accelerated Research Therapeutics (START), San Antonio

80218

RECRUITING

Rocky Mountain Cancer Center, Denver

85258

COMPLETED

HonorHealth, Scottsdale

06519

RECRUITING

Yale Cancer Center, New Haven

02114

RECRUITING

Mass General Cancer Center, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston